SC83288 is a clinical development candidate for the treatment of severe malaria

Stefano Pegoraro; Maëlle Duffey; Thomas D Otto; Yulin Wang; Roman Rösemann; Roland Baumgartner; Stefanie K Fehler; Leonardo Lucantoni; Vicky M Avery; Alicia Moreno-Sabater; Dominique Mazier; Henri J Vial; Stefan Strobl; Cecilia P Sanchez; Michael Lanzer

doi:10.1038/ncomms14193

Nature Communications (Jan 2017)

SC83288 is a clinical development candidate for the treatment of severe malaria

Stefano Pegoraro,
Maëlle Duffey,
Thomas D Otto,
Yulin Wang,
Roman Rösemann,
Roland Baumgartner,
Stefanie K Fehler,
Leonardo Lucantoni,
Vicky M Avery,
Alicia Moreno-Sabater,
Dominique Mazier,
Henri J Vial,
Stefan Strobl,
Cecilia P Sanchez,
Michael Lanzer

Affiliations

Stefano Pegoraro: 4SC AG, Am Klopferspitz 19a
Maëlle Duffey: Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg
Thomas D Otto: Parasite Genomics, Wellcome Trust Sanger Institute, Wellcome Genome Campus
Yulin Wang: Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg
Roman Rösemann: 4SC Discovery GmbH, Am Klopferspitz 19a
Roland Baumgartner: 4SC AG, Am Klopferspitz 19a
Stefanie K Fehler: 4SC AG, Am Klopferspitz 19a
Leonardo Lucantoni: Eskitis Institute for Drug Discovery, Griffith University, Don Young
Vicky M Avery: Eskitis Institute for Drug Discovery, Griffith University, Don Young
Alicia Moreno-Sabater: Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l’hôpital
Dominique Mazier: Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l’hôpital
Henri J Vial: Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Université Montpellier II
Stefan Strobl: 4SC Discovery GmbH, Am Klopferspitz 19a
Cecilia P Sanchez: Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg
Michael Lanzer: Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg

DOI: https://doi.org/10.1038/ncomms14193
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 17

Abstract

Read online

Severe malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal